oasis 1 oral semaglutide 50 mg nejm 2023 obesity 25 and Orforglipron for Obesity: New Insights In the OASIS 4 phase

Medication-Induced Weight Change Across Common Antidepressant Treatments

In the pivotal STEP 1 clinical trial, participants who received weekly semaglutide injections lost an average of 14.9% of their body weight over 68 weeks , compared with 2.4% in the placebo group (study in the New England Journal of Medicine )

For most people on semaglutide, 5 grams daily is the target

Across multiple organ systems and injury models, BPC-157 showed cytoprotective effects and no measurable toxicity, even with high cumulative exposure. Sikiric, P

Do not read from the top of the stopper or the curved edge

GLP-1 medications like Ozempic and Wegovy are widely used for type 2 diabetes and, increasingly, for medical weight management